American Association for Cancer Research to Receive Transformational Donation from Pfizer Inc.

PHILADELPHIA – The American Association for Cancer Research (AACR) today announced that Pfizer Inc. has chosen to donate the rights of its royalties from the sale of Bavencio® (avelumab) in the United States to AACR. This unrestricted donation will support AACR, which is the first and largest cancer research organization formed in the world, in its mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, and funding for cancer research.

“We are very proud to directly support AACR’s vital mission,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. “Both Pfizer and AACR are dedicated to accelerating the discovery of new breakthroughs in cancer research and treatment in order to bring new hope to people living with cancer globally.”

“On behalf of AACR, its Board of Directors, and its 58,000 members in 135 countries, I want to extend our heartfelt gratitude to Pfizer for its generous and impactful gift in support of our mission to defeat cancer in all its forms. We are absolutely delighted that AACR has been chosen because of our sustained innovation in cancer research,” said Margaret Foti, PhD, MD (hc), Chief Executive Officer, AACR. “This significant donation will further advance cutting-edge science and catapult the development of lifesaving discoveries against cancer.”